Aims and Scope of ACS Medicinal Chemistry Letters
ACS Medicinal Chemistry Letters is a peer-reviewed academic journal in the field of medicinal chemistry. Founded in 2009, this online journal is published monthly by the American Chemical Society. The Editor-in-Chief is Dennis C. Liotta (Emory University, Atlanta, Georgia, USA). Less
Key Metrics
CiteScore 

6.6
Eigenfactor 

0.01 - 0.05
Impact Factor 

< 5
SJR 

Q2Biochemistry

SNIP 

0.93
Recommended pre-submission checks
Powered by 

Topics Covered on ACS Medicinal Chemistry Letters
ACS Medicinal Chemistry Letters Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
SJR
| Overview | |
| Publisher | AMER CHEMICAL SOC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2010 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in ACS Medicinal Chemistry Letters ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in ACS Medicinal Chemistry Letters
Novel 3‑Heteroaryl Pyrrolidine and Piperidine Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, namely, Narcolepsy and Hypersomnia.
- 14 May 2026
- ACS medicinal chemistry letters
Spirocyclohexane-Chroman-4-one Derivatives as Selectively Cytotoxic Agents in Breast Cancer Models.
- 14 May 2026
- ACS medicinal chemistry letters
Novel Pyrrolopyridazine Compounds as VEGFR Inhibitors for Treating Cancer.
- 14 May 2026
- ACS medicinal chemistry letters
Exatecan Payload-Based Antibody-Drug Conjugates with a Short Hydrophilic Cleavable Linker.
- 14 May 2026
- ACS medicinal chemistry letters
Advancing KRAS Modulation: Expanding Chemical Space toward Broad-Spectrum RAS-Driven Oncology.
- 14 May 2026
- ACS medicinal chemistry letters
Drug Discovery in Africa.
- 14 May 2026
- ACS medicinal chemistry letters
Novel 3‑Heteroaryl Pyrrolidine and Piperidine Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, namely, Narcolepsy and Hypersomnia.
- 14 May 2026
- ACS medicinal chemistry letters
Spirocyclohexane-Chroman-4-one Derivatives as Selectively Cytotoxic Agents in Breast Cancer Models.
- 14 May 2026
- ACS medicinal chemistry letters
Novel Pyrrolopyridazine Compounds as VEGFR Inhibitors for Treating Cancer.
- 14 May 2026
- ACS medicinal chemistry letters
Exatecan Payload-Based Antibody-Drug Conjugates with a Short Hydrophilic Cleavable Linker.
- 14 May 2026
- ACS medicinal chemistry letters
Advancing KRAS Modulation: Expanding Chemical Space toward Broad-Spectrum RAS-Driven Oncology.
- 14 May 2026
- ACS medicinal chemistry letters
Drug Discovery in Africa.
- 14 May 2026
- ACS medicinal chemistry letters